ZA200708444B - Agent for prevention or treatment of nocturnal behavioral disorder associated with dementia - Google Patents

Agent for prevention or treatment of nocturnal behavioral disorder associated with dementia

Info

Publication number
ZA200708444B
ZA200708444B ZA200708444A ZA200708444A ZA200708444B ZA 200708444 B ZA200708444 B ZA 200708444B ZA 200708444 A ZA200708444 A ZA 200708444A ZA 200708444 A ZA200708444 A ZA 200708444A ZA 200708444 B ZA200708444 B ZA 200708444B
Authority
ZA
South Africa
Prior art keywords
dementia
prevention
agent
treatment
disorder associated
Prior art date
Application number
ZA200708444A
Other languages
English (en)
Inventor
Hirai Keisuke
Miyamoto Masaomi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200708444(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ZA200708444B publication Critical patent/ZA200708444B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA200708444A 2005-04-04 2006-04-03 Agent for prevention or treatment of nocturnal behavioral disorder associated with dementia ZA200708444B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005107673 2005-04-04

Publications (1)

Publication Number Publication Date
ZA200708444B true ZA200708444B (en) 2009-03-25

Family

ID=37073568

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708444A ZA200708444B (en) 2005-04-04 2006-04-03 Agent for prevention or treatment of nocturnal behavioral disorder associated with dementia

Country Status (20)

Country Link
US (1) US20090306200A1 (fr)
EP (1) EP1867642A4 (fr)
JP (1) JP5244384B2 (fr)
KR (1) KR20070118101A (fr)
CN (1) CN101146787A (fr)
AR (1) AR054246A1 (fr)
AU (1) AU2006231759A1 (fr)
BR (1) BRPI0609964A2 (fr)
CA (1) CA2601988A1 (fr)
CL (1) CL2009001914A1 (fr)
CR (1) CR9376A (fr)
IL (1) IL185936A0 (fr)
MA (1) MA29400B1 (fr)
MY (1) MY148806A (fr)
NO (1) NO20075600L (fr)
PE (1) PE20061292A1 (fr)
RU (1) RU2007140876A (fr)
TW (1) TW200637541A (fr)
WO (1) WO2006107027A1 (fr)
ZA (1) ZA200708444B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
EP3400940B1 (fr) 2016-01-08 2024-08-07 Takeda Pharmaceutical Company Limited Acomposés ayant une affinité pour le récepteur de la mélatonine en tant qu'agent prophylactique ou thérapeutique du délire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034239A (en) * 1961-04-05 1962-05-15 Arthur P Waterson Land leveler
US6638963B1 (en) * 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
WO2004015081A2 (fr) * 2002-08-08 2004-02-19 Irm Llc Procedes de traitement de troubles de phases du rythme circadien

Also Published As

Publication number Publication date
CL2009001914A1 (es) 2010-02-12
EP1867642A1 (fr) 2007-12-19
AU2006231759A1 (en) 2006-10-12
KR20070118101A (ko) 2007-12-13
AR054246A1 (es) 2007-06-13
WO2006107027A1 (fr) 2006-10-12
TW200637541A (en) 2006-11-01
MA29400B1 (fr) 2008-04-01
EP1867642A4 (fr) 2009-04-01
CN101146787A (zh) 2008-03-19
JPWO2006107027A1 (ja) 2008-09-25
BRPI0609964A2 (pt) 2011-10-11
CR9376A (es) 2007-12-07
IL185936A0 (en) 2008-01-06
JP5244384B2 (ja) 2013-07-24
US20090306200A1 (en) 2009-12-10
RU2007140876A (ru) 2009-05-20
CA2601988A1 (fr) 2006-10-12
MY148806A (en) 2013-05-31
NO20075600L (no) 2007-12-21
PE20061292A1 (es) 2006-12-23

Similar Documents

Publication Publication Date Title
EP2318005A4 (fr) Agents neuroprotecteurs pour la prévention et le traitement de maladies neurodégénératives
EP2004630A4 (fr) 2-aminopyrimidin-4-ones et leur utilisation pour le traitement ou la prevention de pathologies liees a la proteine a
PL2118074T3 (pl) Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
EP2170311A4 (fr) Compositions et procédés pour traiter ou empêcher des maladies auto-immunes
ZA200907575B (en) C3b antobodies and methods for the prevention and treatment of complement associated disorders
IL200766A0 (en) Compositions and methods for the prevention and treatment of autoimmune conditions
AP2007004245A0 (en) Compounds and methods for the treatment or prevention of flavivirus infections
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
IL209895A (en) Compounds for the prevention and / or treatment of β-amyloidoses
PL2254589T3 (pl) Związki i sposoby zapobiegania lub leczenia restenozy
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
EP2023874A4 (fr) Procédés d'identification d'agents et leur utilisation pour la prévention d'une resténose
PL1998730T3 (pl) Nowy system uciskowy do leczenia i zapobiegania patologiom pochodzenia żylnego
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
ZA200707472B (en) Diosmetin derivatives for the treatment and prevention of thrombotic pathologies
SI2234631T1 (sl) Spojine in postopki za zdravljenje ĺ˝ilne bolezni
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
PL1905452T3 (pl) Środek do zapobiegania lub leczenia jaskry
IL197766A0 (en) Use of oritavancin for the prevention and treatment of anthrax
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
IL197533A0 (en) Composition for the treatment and/or prevention of fire blight
IL226363A0 (en) Compounds and methods for treating cancer
IL185936A0 (en) Agent for prevention or treatment of nocturnal behavioral disorder associated with dimentia
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease